



**ABC Talking Points on Convalescent Plasma**  
*(April 3, 2020)*

The entire blood community is working closely with the U.S. Food and Drug Administration (FDA) to begin collecting and distributing convalescent plasma from individuals who have recovered from COVID-19.

While COVID-19 currently has no proven treatment, it is possible that convalescent plasma that contains antibodies to SARS-CoV-2 (the virus that causes COVID-19) may provide passive immunity to certain patients with severe forms of COVID-19.

Individuals may be eligible to donate convalescent plasma if they meet all regular blood donor requirements and meet the following minimum requirements:

- prior diagnosis for COVID-19 by laboratory test and complete resolution of symptoms for at least 28 days or;
- prior diagnosis for COVID-19 by laboratory test and complete resolution of symptoms for at least 14 days with a follow-up negative COVID-19 test or;
- prior diagnosis for COVID-19 by clinical symptoms/evaluation and complete resolution of symptoms for at least 28 days; or
- prior diagnosis for COVID-19 by clinical symptoms/evaluation and complete resolution of symptoms for at least 14 days with a follow-up negative COVID-19 test.

If the individual meets the criteria above, the donor center will further evaluate their eligibility which will include routine donor screening as well as possible additional pre-screen and testing related to COVID.

Individuals who have had a confirmed case of COVID-19 and have since experienced a full recovery should contact their local blood center to determine their eligibility. To find the blood center closest to you, visit <https://americasblood.org/for-donors/find-a-blood-center/>.

Physicians and hospitals can learn more by visiting the FDA website on convalescent plasma emergency use at: <https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds>.